biotech · Pediatric acute-onset neuropsychiatric syndrome (PANS) · acute hereditary angioedema attacks · MAZE
Maze Therapeutics
Maze Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker MAZE. Primary therapeutic focus areas include Pediatric acute-onset neuropsychiatric syndrome (PANS),
South San Francisco, USA HQ
2018 Founded
152 Employees
Public company Type
MAZE · NYSE Ticker
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2018
- Employees
- 152
- Programs
- 8
- Drugs
- 12
- Patents
- 60
NGAM-13
Phase 3 · small molecule · Pediatric acute-onset neuropsychiatric syndrome (PANS)
NGAM-13 for Pediatric acute-onset neuropsychiatric syndrome (PANS) is a Phase 3 program (small_molecule) at Maze Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code NGAM-13
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Maze Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Pediatric acute-onset neuropsychiatric syndrome (PANS)
- Status
- active
- Trials
- 1